No Data
No Data
Express News | JMP Securities Reiterates Market Outperform on Esperion Therapeutics, Maintains $7 Price Target
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 A.m. ET.
BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating, Maintains Target Price $2.05
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt
Growth Investor27 : I own a lot & will buy more
DazzlerAus : agree but nothing seems to help
Youngman : I keep hearing nothing but good things about the stock while it goes down lol